HK1163134A1 - Antibodies to ccr2 ccr2 - Google Patents
Antibodies to ccr2 ccr2Info
- Publication number
- HK1163134A1 HK1163134A1 HK12103743.0A HK12103743A HK1163134A1 HK 1163134 A1 HK1163134 A1 HK 1163134A1 HK 12103743 A HK12103743 A HK 12103743A HK 1163134 A1 HK1163134 A1 HK 1163134A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ccr2
- antibodies
- ccr2 ccr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18935708P | 2008-08-18 | 2008-08-18 | |
PCT/US2009/004711 WO2010021697A2 (en) | 2008-08-18 | 2009-08-17 | Antibodies to ccr2 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1163134A1 true HK1163134A1 (en) | 2012-09-07 |
Family
ID=41347729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12103743.0A HK1163134A1 (en) | 2008-08-18 | 2012-04-17 | Antibodies to ccr2 ccr2 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8710191B2 (xx) |
EP (1) | EP2321351B1 (xx) |
JP (1) | JP5685535B2 (xx) |
KR (1) | KR101772706B1 (xx) |
CN (1) | CN102239180B (xx) |
AU (1) | AU2009283199B2 (xx) |
BR (1) | BRPI0916973A2 (xx) |
CA (1) | CA2734578C (xx) |
CO (1) | CO6351802A2 (xx) |
DK (1) | DK2321351T3 (xx) |
ES (1) | ES2658117T3 (xx) |
HK (1) | HK1163134A1 (xx) |
IL (1) | IL211284A (xx) |
MX (1) | MX2011001911A (xx) |
MY (1) | MY160892A (xx) |
NO (1) | NO2321351T3 (xx) |
NZ (1) | NZ591471A (xx) |
PE (1) | PE20110774A1 (xx) |
RU (1) | RU2547595C2 (xx) |
SG (2) | SG10201701323TA (xx) |
WO (1) | WO2010021697A2 (xx) |
ZA (1) | ZA201101047B (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011116299A2 (en) * | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
US20110038871A1 (en) * | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
EP3539987A1 (en) * | 2011-01-10 | 2019-09-18 | NovImmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
EP2718312B1 (en) | 2011-06-13 | 2018-07-25 | TLA Targeted Immunotherapies AB | Treating conditions associated with sepsis |
WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
ES2821375T3 (es) | 2011-06-13 | 2021-04-26 | Tla Targeted Immunotherapies Ab | Tratamiento de afecciones respiratorias |
WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
DK2718311T3 (en) | 2011-06-13 | 2018-04-16 | Tla Targeted Immunotherapies Ab | TREATMENT OF MULTIPLE SCLEROSIS |
WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
WO2012172339A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory arthritis |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
WO2013041833A1 (en) | 2011-06-13 | 2013-03-28 | Ith Immune Therapy Holdings Ab | Treating conditions associated with metabolic syndrome |
US20140349321A1 (en) * | 2011-12-16 | 2014-11-27 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
EP2864358B1 (en) * | 2012-06-22 | 2019-08-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
EP3262418B1 (en) * | 2015-02-26 | 2019-05-01 | Innovative Concepts in Drug Development | Diagnostic markers of cognitive impairments, kits and uses thereof |
PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CA3022765A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
CN109415432B (zh) | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | Tau免疫疗法 |
CN115154467A (zh) * | 2016-06-03 | 2022-10-11 | 坎莫森特里克斯公司 | 治疗肝纤维化的方法 |
RU2765737C2 (ru) | 2016-11-23 | 2022-02-02 | Хемоцентрикс, Инк. | Способ лечения фокально-сегментарного гломерулосклероза |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
US10758540B2 (en) | 2017-10-11 | 2020-09-01 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists |
JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
JP7330977B2 (ja) | 2017-12-19 | 2023-08-22 | スロゼン オペレーティング, インコーポレイテッド | Wntサロゲート分子及びその使用 |
AU2019299217A1 (en) * | 2018-07-03 | 2021-01-14 | Fennec Pharmaceuticals, Inc. | Formulations of anhydrous sodium thiosulfate |
EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES |
US20220242957A1 (en) | 2018-09-27 | 2022-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
SG11202106525TA (en) | 2018-12-24 | 2021-07-29 | Sanofi Sa | Multispecific binding proteins with mutant fab domains |
US20220146534A1 (en) * | 2019-01-16 | 2022-05-12 | Yeda Research And Development, Co., Ltd. | Biomarkers for CNS Disease Modification |
CU20210073A7 (es) | 2019-03-03 | 2022-04-07 | Prothena Biosciences Ltd | Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs |
TW202110477A (zh) * | 2019-04-17 | 2021-03-16 | 國立大學法人廣島大學 | 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑 |
WO2020232127A1 (en) * | 2019-05-13 | 2020-11-19 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind ccr2 to modulate cellular function |
EP3990499A4 (en) * | 2019-06-26 | 2023-07-05 | Amunix Pharmaceuticals, Inc. | EGFR ANTIGEN-BINDING FRAGMENTS AND COMPOSITIONS COMPRISING THEM |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20220025436A1 (en) * | 2020-07-21 | 2022-01-27 | Rutgers, The State University Of New Jersey | Method and Kit For CCR2 Expression Profiling And Disease Stratification |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
CA3231124A1 (en) | 2021-10-27 | 2023-05-04 | Matthias Mack | Antibodies targeting ccr2 |
CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
NZ246242A (en) * | 1991-12-02 | 1996-01-26 | Cor Therapeutics Inc | Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf) |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2218489A1 (en) | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SE9600820D0 (sv) * | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 cd147 결합 분자 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
US20030165988A1 (en) * | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
DK1461300T3 (da) | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
WO2003066830A2 (en) | 2002-02-08 | 2003-08-14 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
RU2339647C2 (ru) | 2002-08-19 | 2008-11-27 | Астразенека Аб | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
DK1538207T3 (da) | 2002-09-12 | 2010-07-05 | Chemo Sero Therapeut Res Inst | Humant anti-human MCP-1-antistof og antistoffragment deraf |
JP2007521248A (ja) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヒト化抗ccr2抗体および該抗体を使用する方法 |
EP1753783B1 (en) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
US7371825B2 (en) | 2004-06-30 | 2008-05-13 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
RU2007103332A (ru) | 2004-07-30 | 2008-08-10 | Пфайзер Продактс Инк. (Us) | Способы лечения опосредуемых ccr2 заболеваний или нарушений |
EP2068920A2 (en) | 2006-10-05 | 2009-06-17 | Centocor Ortho Biotech, Inc. | Ccr2 antagonists for treatment of fibrosis |
-
2009
- 2009-08-17 CN CN200980136307.1A patent/CN102239180B/zh not_active Expired - Fee Related
- 2009-08-17 PE PE2011000160A patent/PE20110774A1/es active IP Right Grant
- 2009-08-17 SG SG10201701323TA patent/SG10201701323TA/en unknown
- 2009-08-17 AU AU2009283199A patent/AU2009283199B2/en not_active Ceased
- 2009-08-17 WO PCT/US2009/004711 patent/WO2010021697A2/en active Application Filing
- 2009-08-17 SG SG2013063318A patent/SG193216A1/en unknown
- 2009-08-17 US US13/059,702 patent/US8710191B2/en active Active
- 2009-08-17 DK DK09789161.8T patent/DK2321351T3/en active
- 2009-08-17 MX MX2011001911A patent/MX2011001911A/es active IP Right Grant
- 2009-08-17 JP JP2011523807A patent/JP5685535B2/ja active Active
- 2009-08-17 KR KR1020117006355A patent/KR101772706B1/ko active IP Right Grant
- 2009-08-17 MY MYPI2011000512A patent/MY160892A/en unknown
- 2009-08-17 RU RU2011110169/10A patent/RU2547595C2/ru active
- 2009-08-17 NZ NZ591471A patent/NZ591471A/xx unknown
- 2009-08-17 NO NO09789161A patent/NO2321351T3/no unknown
- 2009-08-17 BR BRPI0916973A patent/BRPI0916973A2/pt not_active IP Right Cessation
- 2009-08-17 ES ES09789161.8T patent/ES2658117T3/es active Active
- 2009-08-17 CA CA2734578A patent/CA2734578C/en active Active
- 2009-08-17 EP EP09789161.8A patent/EP2321351B1/en active Active
-
2011
- 2011-02-09 ZA ZA2011/01047A patent/ZA201101047B/en unknown
- 2011-02-17 IL IL211284A patent/IL211284A/en active IP Right Grant
- 2011-03-11 CO CO11030038A patent/CO6351802A2/es active IP Right Grant
-
2012
- 2012-04-17 HK HK12103743.0A patent/HK1163134A1/xx not_active IP Right Cessation
-
2014
- 2014-04-03 US US14/244,167 patent/US9238691B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1163134A1 (en) | Antibodies to ccr2 ccr2 | |
HK1217711A1 (zh) | 特異於鈣粘素- 的抗體 | |
IL214996A0 (en) | Anti-bcma antibodies | |
GB0920127D0 (en) | Antibodies | |
ZA201102119B (en) | Improved antibody libraies | |
GB0909906D0 (en) | Antibodies | |
EP2220247A4 (en) | ANTIBODIES DIRECTED AGAINST LRP6 | |
ZA201003876B (en) | Antibodies to gdf8 as uses thereof | |
EP3064512C0 (en) | ANTIBODIES AGAINST CLDN6 | |
GB0821100D0 (en) | Antibodies | |
ZA201007955B (en) | Anti-cxcr4 antibodies | |
EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
EP2125890A4 (en) | ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4 | |
EP2212431A4 (en) | ANTI-IREM-1 ANTIBODIES | |
ZA201006099B (en) | Anti-tyrp1 antibodies | |
PL2488554T3 (pl) | Przeciwciała przeciw epha3 | |
GB0920324D0 (en) | Antibodies | |
ZA201007976B (en) | Anti-pirb antibodies | |
GB0818356D0 (en) | Antibodies | |
EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
EP2424892A4 (en) | DC-STAMP ANTIBODY | |
GB0911770D0 (en) | Antibody | |
GB0801891D0 (en) | Brekkie to go range | |
GB0806230D0 (en) | Antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF APPLICANT/PROPRIETOR: AMGEN FREMONT INC |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200813 |